Decoding Alzheimer's Disease: Acetylcholine and Dopamine Pathway Disruptions As Early Markers of Cognitive Decline

Overview

Journal Brain Commun

Publisher Oxford University Press

Specialty Neurology

Date 2025 Feb 21

PMID 39980741

Authors

Claudio Zaccone

Annalisa Nobili

Marcello DAmelio

Affiliations

Soon will be listed here.

Abstract

This scientific commentary refers to 'Changes in neurotransmitter-related functional connectivity along the Alzheimer's disease continuum', by Manca . (https://doi.org/10.1093/braincomms/fcaf008).

References

Wearn A, Tremblay S, Tardif C, Leppert I, Gauthier C, Baracchini G . Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status. Nat Commun. 2024; 15(1):4706. PMC: 11148077. DOI: 10.1038/s41467-024-48490-z. View

Herrup K . The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015; 18(6):794-9. DOI: 10.1038/nn.4017. View

Koch G, Esposito Z, Codeca C, Mori F, Kusayanagi H, Monteleone F . Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. Clin Neurophysiol. 2010; 122(4):703-7. DOI: 10.1016/j.clinph.2010.10.033. View

Sun Q, Zhang J, Li A, Yao M, Liu G, Chen S . Acetylcholine deficiency disrupts extratelencephalic projection neurons in the prefrontal cortex in a mouse model of Alzheimer's disease. Nat Commun. 2022; 13(1):998. PMC: 8863829. DOI: 10.1038/s41467-022-28493-4. View

Kim C, Lee Y, Ong L, Gold M, Kalali A, Sarkar J . Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. J Alzheimers Dis. 2022; 87(1):83-100. PMC: 9198803. DOI: 10.3233/JAD-215699. View

Chakraborty S, Lennon J, Malkaram S, Zeng Y, Fisher D, Dong H . Serotonergic system, cognition, and BPSD in Alzheimer's disease. Neurosci Lett. 2019; 704:36-44. PMC: 6594906. DOI: 10.1016/j.neulet.2019.03.050. View

Serra L, DAmelio M, Di Domenico C, Dipasquale O, Marra C, Mercuri N . In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease. Neurobiol Aging. 2018; 72:72-82. DOI: 10.1016/j.neurobiolaging.2018.08.012. View

Possemato E, La Barbera L, Nobili A, Krashia P, DAmelio M . The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases. Ageing Res Rev. 2023; 87:101907. DOI: 10.1016/j.arr.2023.101907. View

Heneka M, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D . Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010; 107(13):6058-63. PMC: 2851853. DOI: 10.1073/pnas.0909586107. View

10.

Manca R, De Marco M, Soininen H, Ruffini L, Venneri A . Changes in neurotransmitter-related functional connectivity along the Alzheimer's disease continuum. Brain Commun. 2025; 7(1):fcaf008. PMC: 11840171. DOI: 10.1093/braincomms/fcaf008. View

11.

Hampel H, Mesulam M, Cuello A, Farlow M, Giacobini E, Grossberg G . The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018; 141(7):1917-1933. PMC: 6022632. DOI: 10.1093/brain/awy132. View

12.

Nobili A, Latagliata E, Viscomi M, Cavallucci V, Cutuli D, Giacovazzo G . Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nat Commun. 2017; 8:14727. PMC: 5382255. DOI: 10.1038/ncomms14727. View